ECSP099036A - Moduladores del metabolismo y tratamiento de los trastornos metabólicos - Google Patents

Moduladores del metabolismo y tratamiento de los trastornos metabólicos

Info

Publication number: ECSP099036A
Authority: EC; Ecuador
Prior art keywords: treatment; metabolic disorders; metabolism modulators; methyl; modulators
Prior art date: 2006-07-06

Application number

EC2009009036A

Other languages

English (en)

Spanish (es)

Inventor

Juerg Lehmann

Robert M Jones

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-06

Filing date

2009-01-06

Publication date

2009-02-27

2009-01-06 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2009-02-27 Publication of ECSP099036A publication Critical patent/ECSP099036A/es

Links

208000030159 metabolic disease Diseases 0.000 title abstract 2
230000004060 metabolic process Effects 0.000 title 1
208000008589 Obesity Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000004153 glucose metabolism Effects 0.000 abstract 1
150000004677 hydrates Chemical class 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
BTVNNMSDLVBWRW-UHFFFAOYSA-N propan-2-yl 4-[5-methyl-6-[(2-methyl-6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC1OC1=NC=NC(NC=2C(=NC(=CC=2)S(C)(=O)=O)C)=C1C BTVNNMSDLVBWRW-UHFFFAOYSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Obesity (AREA)
Cardiology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Neurology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EC2009009036A 2006-07-06 2009-01-06 Moduladores del metabolismo y tratamiento de los trastornos metabólicos ECSP099036A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US81950006P	2006-07-06	2006-07-06

Publications (1)

Publication Number	Publication Date
ECSP099036A true ECSP099036A (es)	2009-02-27

Family

ID=38707392

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EC2009009036A ECSP099036A (es)	2006-07-06	2009-01-06	Moduladores del metabolismo y tratamiento de los trastornos metabólicos

Country Status (26)

Country	Link
US (1)	US20100004272A1 (2)
EP (1)	EP2049523A1 (2)
JP (1)	JP2009542702A (2)
KR (1)	KR20090024779A (2)
CN (1)	CN101484440A (2)
AR (1)	AR061967A1 (2)
AU (1)	AU2007269577A1 (2)
BR (1)	BRPI0714006A2 (2)
CA (1)	CA2656520A1 (2)
CL (1)	CL2007001972A1 (2)
CO (1)	CO6160320A2 (2)
CR (1)	CR10538A (2)
EA (1)	EA015343B1 (2)
EC (1)	ECSP099036A (2)
GT (1)	GT200800305A (2)
IL (1)	IL195819A0 (2)
MA (1)	MA30601B1 (2)
MX (1)	MX2008016251A (2)
NI (1)	NI200800328A (2)
NO (1)	NO20090590L (2)
PE (1)	PE20080737A1 (2)
TN (1)	TNSN08534A1 (2)
TW (1)	TW200811140A (2)
UY (1)	UY30466A1 (2)
WO (1)	WO2008005576A1 (2)
ZA (1)	ZA200900051B (2)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MXPA05007485A (es)	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101452915B1 (ko)	2006-05-04	2014-10-21	베링거 인겔하임 인터내셔날 게엠베하	다형태
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2443699C2 (ru)	2007-09-20	2012-02-27	Айрм Ллк	Соединения и композиции в качестве модуляторов активности gpr119
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2736421A1 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010059384A1 (en) *	2008-10-30	2010-05-27	Janssen Pharmaceutica Nv	Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
JP2012512848A (ja)	2008-12-23	2012-06-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	有機化合物の塩の形態
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
JP5657518B2 (ja)	2009-02-18	2015-01-21	武田薬品工業株式会社	縮合複素環化合物
US8481731B2 (en)	2009-06-24	2013-07-09	Boehringer Ingelheim International Gmbh	Compounds, pharmaceutical composition and methods relating thereto
EA201200046A1 (ru)	2009-06-24	2012-08-30	Бёрингер Ингельхайм Интернациональ Гмбх	Новые соединения, фармацевтическая композиция и связанные с ними способы
US9086928B2 (en) *	2009-08-31	2015-07-21	Accenture Global Services Limited	Provisioner within cloud console—defining images of an enterprise to be operable on different cloud computing providers
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
SG10201906876PA (en)	2010-01-27	2019-09-27	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja)	2010-03-18	2013-06-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
CA3070513C (en)	2010-05-05	2023-01-03	Boehringer Ingelheim International Gmbh	A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
KR20130093012A (ko)	2010-06-24	2013-08-21	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012025811A1 (en)	2010-08-23	2012-03-01	Lupin Limited	Indolylpyrimidines as modulators of gpr119
PH12013500547A1 (en)	2010-09-22	2013-06-10	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9000175B2 (en)	2010-11-26	2015-04-07	Lupin Limited	Bicyclic GPR119 modulators
KR101913619B1 (ko)	2011-06-09	2018-12-28	리젠 파마슈티컬스 소시에떼 아노님	Gpr-119의 조절제로서의 신규한 화합물
DK2731947T3 (en)	2011-07-15	2019-04-23	Boehringer Ingelheim Int	SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
US9755858B2 (en) *	2014-04-15	2017-09-05	Cisco Technology, Inc.	Programmable infrastructure gateway for enabling hybrid cloud services in a network environment
MX386419B (es)	2015-01-06	2025-03-18	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
CN104761540A (zh) *	2015-03-12	2015-07-08	佛山市赛维斯医药科技有限公司	一种含烟酸酰胺和哌啶结构的化合物及其用途
CN106748999A (zh) *	2015-03-12	2017-05-31	佛山市赛维斯医药科技有限公司	一类含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104788424A (zh) *	2015-03-12	2015-07-22	佛山市赛维斯医药科技有限公司	含烟酸酰胺和哌啶结构的ptp1b抑制剂、制备方法及其用途
CN104725310A (zh) *	2015-03-12	2015-06-24	佛山市赛维斯医药科技有限公司	一种含烟酸酰胺和苯胺结构的ptp1b抑制剂及其用途
CN104725311A (zh) *	2015-03-12	2015-06-24	佛山市赛维斯医药科技有限公司	含烟酸酰胺结构的ptp1b抑制剂及其用途
CN104725307A (zh) *	2015-03-12	2015-06-24	佛山市赛维斯医药科技有限公司	一种含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN104788425A (zh) *	2015-03-12	2015-07-22	佛山市赛维斯医药科技有限公司	一类含烟酸酰胺和哌啶结构ptp1b抑制剂、制备方法及其用途
CN106831561A (zh) *	2015-03-12	2017-06-13	佛山市赛维斯医药科技有限公司	一种含烟酸酰胺和苯胺结构的ptp1b抑制剂、其制备及用途
CN104725308A (zh) *	2015-03-12	2015-06-24	佛山市赛维斯医药科技有限公司	含烟酸酰胺结构的ptp1b抑制剂、制备方法及其用途
CN106749179A (zh) *	2015-03-12	2017-05-31	佛山市赛维斯医药科技有限公司	一种含烟酸酰胺和哌啶结构ptp1b抑制剂及其用途
CN104725309A (zh) *	2015-03-12	2015-06-24	佛山市赛维斯医药科技有限公司	一种含烟酸酰胺结构的ptp1b抑制剂及其用途
EP3939965A1 (en)	2015-06-22	2022-01-19	Arena Pharmaceuticals, Inc.	Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
EP4233840A3 (en)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin
MA47504A (fr)	2017-02-16	2019-12-25	Arena Pharm Inc	Composés et méthodes de traitement de l'angiocholite biliaire primitive
CN107145725A (zh) *	2017-04-26	2017-09-08	江南大学	一种分析餐厨垃圾厌氧消化产甲烷能力的方法
ES2987794T3 (es)	2018-06-06	2024-11-18	Arena Pharm Inc	Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH478817A (de) *	1965-10-22	1969-09-30	Ciba Geigy	Verfahren zur Herstellung neuer N,N'-Di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanen
CH480410A (de) *	1967-01-09	1969-10-31	Geigy Ag J R	Verfahren zur Herstellung von wasserlöslichen Azopyrimidinfarbstoffen
CA961052A (en) *	1967-01-12	1975-01-14	Max Schellenbaum	N-2-ethylhexyl-n'-aryl ureas and preparation containing them
US3608087A (en) *	1968-06-21	1971-09-21	Merck & Co Inc	Feed compositions
US3887329A (en) *	1969-05-05	1975-06-03	Ciba Geigy Ag	Hexamethyl phosphotriamide-dye compositions
US3686238A (en) *	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) *	1970-09-11	1974-12-03	Merck & Co Inc	Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3690834A (en) *	1971-01-11	1972-09-12	Syva Co	Ligand determination with spin labeled compounds by receptor displacement
US3966744A (en) *	1971-01-11	1976-06-29	Syva Company	Spin labeled compounds
DE2106585A1 (de) *	1971-02-11	1972-08-24	Farbenfabriken Bayer Ag, 5090 Leverkusen	Aminothiodiazole und Thiodiazol-Azofarbstoffe
US3966764A (en) *	1972-07-10	1976-06-29	Syva Company	Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) *	1972-10-20	1974-11-19	Dow Chemical Co	Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (2) *	1972-11-16	1976-04-15	Ciba Geigy Ag
DE2340569C2 (de) *	1973-08-10	1982-12-02	Bayer Ag, 5090 Leverkusen	Azofarbstoffe
AT340933B (de) *	1973-08-20	1978-01-10	Thomae Gmbh Dr K	Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US4101541A (en) *	1973-12-21	1978-07-18	Ciba-Geigy Corporation	3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
FR2306697A1 (fr) *	1975-04-10	1976-11-05	Sogeras	Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
DE2731264A1 (de) *	1977-07-11	1979-02-01	Boehringer Mannheim Gmbh	Neue 1-acyl-2-cyanaziridine, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zubereitungen
JPS6038696B2 (ja) *	1977-12-09	1985-09-02	コニカ株式会社	ハロゲン化銀カラ−写真感光材料
US4242507A (en) *	1978-02-23	1980-12-30	Fujisawa Pharmaceutical Co., Ltd.	Sulfonic acid esters
DE2831580C2 (de) *	1978-07-18	1980-09-18	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren und Reagens zur Bestimmung von Glycerin
DE2906603A1 (de) *	1979-02-21	1980-09-04	Boehringer Mannheim Gmbh	N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
DOP1981004033A (es) *	1980-12-23	1990-12-29	Ciba Geigy Ag	Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
DE3334455A1 (de) *	1983-03-04	1984-09-06	Bayer Ag, 5090 Leverkusen	Guanidin - derivate
ZA848275B (en) *	1983-12-28	1985-08-28	Degussa	New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3601196A1 (de) *	1986-01-17	1987-07-23	Merck Patent Gmbh	1,4-dihydropyridine
US5364865A (en) *	1992-12-30	1994-11-15	Sterling Winthrop Inc.	Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
FI970967A7 (fi) *	1994-09-09	1997-03-07	Nippon Shinyaku Co Ltd	Heterosyklinen johdannainen ja lääkeaine
US5691364A (en) *	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US6956047B1 (en) *	1995-06-06	2005-10-18	Pfizer Inc.	Corticotropin releasing factor antagonists
US5849759A (en) *	1995-12-08	1998-12-15	Berlex Laboratories, Inc.	Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5948786A (en) *	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
AR008789A1 (es) *	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
US6008234A (en) *	1996-09-12	1999-12-28	Berlex Laboratories, Inc.	Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
US6187777B1 (en) *	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6239126B1 (en) *	1998-12-17	2001-05-29	American Home Products Corporation	Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US6414002B1 (en) *	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6545017B1 (en) *	2000-12-08	2003-04-08	3M Innovative Properties Company	Urea substituted imidazopyridines
US6525064B1 (en) *	2000-12-08	2003-02-25	3M Innovative Properties Company	Sulfonamido substituted imidazopyridines
US6545016B1 (en) *	2000-12-08	2003-04-08	3M Innovative Properties Company	Amide substituted imidazopyridines
MXPA05007485A (es) *	2003-01-14	2006-01-30	Arena Pharm Inc	Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
ES2316964T3 (es) *	2003-02-24	2009-04-16	Arena Pharmaceuticals, Inc.	Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa.
US7083933B1 (en) *	2003-05-09	2006-08-01	Prosidion Limited	Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) *	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7132426B2 (en) *	2003-07-14	2006-11-07	Arena Pharmaceuticals, Inc.	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EA011671B1 (ru) *	2004-06-04	2009-04-28	Арена Фармасьютикалз, Инк.	Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
MY148521A (en) *	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

2007
- 2007-07-02 TW TW096124027A patent/TW200811140A/zh unknown
- 2007-07-04 PE PE2007000858A patent/PE20080737A1/es not_active Application Discontinuation
- 2007-07-05 MX MX2008016251A patent/MX2008016251A/es not_active Application Discontinuation
- 2007-07-05 EP EP07810288A patent/EP2049523A1/en not_active Withdrawn
- 2007-07-05 AU AU2007269577A patent/AU2007269577A1/en not_active Withdrawn
- 2007-07-05 JP JP2009518404A patent/JP2009542702A/ja not_active Withdrawn
- 2007-07-05 CN CNA2007800249135A patent/CN101484440A/zh not_active Withdrawn
- 2007-07-05 CA CA002656520A patent/CA2656520A1/en not_active Abandoned
- 2007-07-05 WO PCT/US2007/015681 patent/WO2008005576A1/en not_active Ceased
- 2007-07-05 CL CL200701972A patent/CL2007001972A1/es unknown
- 2007-07-05 BR BRPI0714006-1A patent/BRPI0714006A2/pt not_active IP Right Cessation
- 2007-07-05 KR KR1020097000109A patent/KR20090024779A/ko not_active Withdrawn
- 2007-07-05 US US12/307,545 patent/US20100004272A1/en not_active Abandoned
- 2007-07-05 EA EA200970090A patent/EA015343B1/ru not_active IP Right Cessation
- 2007-07-06 AR ARP070103026A patent/AR061967A1/es unknown
- 2007-07-06 UY UY30466A patent/UY30466A1/es unknown
2008
- 2008-12-09 IL IL195819A patent/IL195819A0/en unknown
- 2008-12-15 NI NI200800328A patent/NI200800328A/es unknown
- 2008-12-19 CR CR10538A patent/CR10538A/es not_active Application Discontinuation
- 2008-12-24 CO CO08136751A patent/CO6160320A2/es unknown
- 2008-12-25 TN TNP2008000534A patent/TNSN08534A1/en unknown
- 2008-12-29 GT GT200800305A patent/GT200800305A/es unknown
2009
- 2009-01-05 ZA ZA200900051A patent/ZA200900051B/xx unknown
- 2009-01-06 EC EC2009009036A patent/ECSP099036A/es unknown
- 2009-01-27 MA MA31590A patent/MA30601B1/fr unknown
- 2009-02-06 NO NO20090590A patent/NO20090590L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2007269577A1 (en)	2008-01-10
CR10538A (es)	2009-01-27
EP2049523A1 (en)	2009-04-22
AR061967A1 (es)	2008-08-10
NO20090590L (no)	2009-02-06
ZA200900051B (en)	2010-01-27
CN101484440A (zh)	2009-07-15
TW200811140A (en)	2008-03-01
UY30466A1 (es)	2008-02-29
BRPI0714006A2 (pt)	2012-12-18
KR20090024779A (ko)	2009-03-09
MX2008016251A (es)	2009-02-25
GT200800305A (es)	2009-04-25
CA2656520A1 (en)	2008-01-10
WO2008005576A1 (en)	2008-01-10
EA200970090A1 (ru)	2009-06-30
IL195819A0 (en)	2009-09-22
EA015343B1 (ru)	2011-06-30
CL2007001972A1 (es)	2008-04-04
JP2009542702A (ja)	2009-12-03
NI200800328A (es)	2010-01-07
MA30601B1 (fr)	2009-07-01
TNSN08534A1 (en)	2010-04-14
US20100004272A1 (en)	2010-01-07
CO6160320A2 (es)	2010-05-20
PE20080737A1 (es)	2008-06-13

Publication	Publication Date	Title
ECSP099036A (es)	2009-02-27	Moduladores del metabolismo y tratamiento de los trastornos metabólicos
ECSP099037A (es)	2009-02-27	Moduladores del metabolismo y tratamiento de los trastornos metabólicos
ECSP088281A (es)	2008-04-28	Moduladores del metabolismo y tratamiento de los trastornos metabólicos
NI200700169A (es)	2008-06-25	Derivados del pirimidinil y piridinil sustituidos como moduladores del metabolismo y el tratamiento de desordenes relacionados con el mismo.
ECSP088747A (es)	2008-10-31	Pirazoles como inhibidores de la 11-beta-hsd1
AR077642A1 (es)	2011-09-14	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CR8122A (es)	2006-05-29	Derivados de arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CO6341563A2 (es)	2011-11-21	Compuestos organicos
BRPI0911035B8 (pt)	2021-05-25	ativadores de pirrolidinona glicoquinase
UY32848A (es)	2011-03-31	Compuestos heterocíclicos de oxima
UY30267A1 (es)	2007-11-30	Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
UY32240A (es)	2010-06-30	Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
CO6491033A2 (es)	2012-07-31	5-3,4-dicloro-fenil- n-(2-hidroxi-cicloheexil)- 6-(2,2,2-trifluoro etoxi)- nicotinamida y sales de la misma, como agentes que elevan el colesterol hdl
AR077958A1 (es)	2011-10-05	Quinoxalinonas antagonistas de la hepcidina
DOP2012000158A (es)	2012-09-30	Derivados de sulfonamida heterociclicos
CL2009001005A1 (es)	2010-06-04	Compuestos derivados de butirato de trimetilamonio, inhibidores de cpt2; proceso de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de enfermedades tales como hiperglucemia, diabetes, hipertension, entre otras patologias.
DOP2004001055A (es)	2006-06-30	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
UY28850A1 (es)	2005-11-30	Inhibidores de la dipeptidil peptidasa iv
ECSP045079A (es)	2004-06-28	Derivados de pirrolidin n-sustituidos como inhibidores de dipeptidil peptidasa iv